Background: Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of RET rearranged metastatic colorectal cancer (mCRC).
Introduction
Gene fusions are found in $1% of metastatic colorectal cancers (mCRC) and represent potentially actionable therapeutic targets [1, 2] . Phylogenetically-related ALK, ROS1 and NTRK1-3 fusions are associated with specific clinical/molecular features and poor prognosis of mCRCs [3] . Tyrosine kinase inhibitors (TKI) such as entrectinib [4] or ceritinib [5] have shown clinical activity in this molecular subgroup and entrectinib received a tissueagnostic FDA breakthrough therapy designation for advanced cancers bearing NTRK1-3 fusions.
RET fusions have been described in a variety of solid tumors including thyroid, non-small-cell lung cancer and a small fraction (<1%) of CRCs [6] [7] [8] . RET over-expression is associated with primary resistance to anti-EGFR agents in RAS and BRAF wildtype CRC preclinical models [2] , whereas RET fusions may be drugged by multi-targeted TKIs such as regorafenib and cabozantinib, or novel selective inhibitors such as RXDX-105.
Here we carried out a multinational effort aimed at unveiling the clinical and molecular landscape of mCRCs harboring RET fusions, in order to potentially help physicians to identify those tumors more likely to be RET rearranged and potentially screen an enriched subgroup rather than all comers.
Materials and methods

Patient population
RET rearranged mCRC cases were retrieved by systematic literature review and by taking advantage of three screening sources ( Figure 1 ): (i) Ignyta's phase 1/1b study on RXDX-105 (NCT01877811), (ii) cohorts screened at two Italian and one South Korean Institutions and (iii) Foundation Medicine database. We were able to retrieve data for 24 RET fusion-positive mCRCs and we compared them with a cohort of 291 RET negative ones. Clinical, pathological and molecular characteristics at the time of diagnosis of mCRC were collected, including age, gender, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), primary tumor location, primary tumor resection, time-to-metastases, microsatellite instability (MSI) and next-generation sequencing data.
All patients signed a written informed consent and this study was centrally approved by the Institutional Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan.
Patients screening and molecular analyses
Independently from fluorescent in-situ hybridization (FISH) or immunohistochemistry (IHC) pre-screening, all RET fusions were confirmed by means of comprehensive genomic profiling [9] or RNA sequencing, as previously described [3] .
Supplementary Table S1 , available at Annals of Oncology online, reports the list of patients bearing RET fusions with screening source, retrieving source, identified gene fusion and NGS panel used.
FISH and IHC analysis
FISH analysis was carried out in three available cases (NCOA4-RET, CCDC6-RET and the novel SNRNP70-RET) by means of a commercially available break-apart (ZytoLight V R SPEC RET Dual Color Break Apart Probe) gene-specific probe at the 10q11.21, according to the manufacturer's protocol. The probe was specifically designed so to identify any rearrangement involving RET, regardless of the partner gene. At least 100 tumor cells were evaluated for each sample following the criteria: (i) two or more fusion orange and green signals (yellowish) indicated RET wildtype (RET-WT) and (ii) one or more fusion yellowish signals (RET-WT), along with separate green and orange signals, identified RET rearrangements. IHC analysis was carried out as previously described [10] .
Statistical analyses
We investigated the association of RET rearrangements with the following variables collected at the diagnosis of mCRC: age, gender, ECOG performance status (0, !1), primary tumour location (right colon, left colon, rectum), primary tumour resection, time to metastases (synchronous, metachronous), RAS and BRAF status (mutated, wild-type), MSI status (MSS, MSI-high). Fisher's exact test, v 2 test or Mann-Whitney tests were used when appropriate to assess the associations of RET rearrangements with investigated characteristics. We investigated the impact of RET rearrangements on overall survival (OS), defined as the time from diagnosis of metastatic disease to death or last follow up for alive patients. OS analysis was determined according to the Kaplan-Meier method and survival curves were compared using the log-rank test. Statistical significance was set at P ¼ 0.05 for a bilateral test. The correlation of RET status and clinicopathological characteristics with OS was assessed in univariate analysis. In order to minimize the bias of multiple comparisons, according to the false discovery rate correction [11] , statistical significance was set at P ¼ 0.006 for a bilateral test. Cox proportional hazard model was adopted in the multivariate analysis, including as covariates variables correlated with survival with P < 0.1 in the univariate analyses. All analyses were carried out by means of Prism 7 for Mac OS X v7.0.
Results
Clinical, pathological and molecular features of RET rearranged mCRC patients
The list and prevalence of specific fusions (mainly NCOA4-RET and CCDC6-RET) is detailed in Figure 1 and the two novel fusions (TNIP1-RET and SNRNP70-RET) are depicted in supplementary Figure S1 , available at Annals of Oncology online.
As shown in Table 1 , RET fusions were more frequent in older patients (median age: 66 versus 60 years, P ¼ 0.052), with ECOG PS 1-2 (90% versus 50%, P ¼ 0.02), right-sided (55% versus 32%, P ¼ 0.013) and unresected primary tumors (58% versus 21%, P < 0.001). Regarding molecular features, all RET rearranged samples were RAS and BRAF wild-type (100% versus 40%, P < 0.001) and a higher proportion was MSI-high (48% versus 7%, P < 0.001). Notably, 11 (26%) out of 43 patients with right-sided, RAS and BRAF wild-type tumors harbored a RET rearrangement. These patients had approximately 10-fold higher chances of harboring RET rearrangements (OR: 9.59; 95% CI, 3.69-24.91; P < 0.001). When considering also MSI status, 6 (67%) out of 9 patients with right-sided, RAS and BRAF wildtype, and MSI-high tumors harbored a RET rearrangement. These patients had approximately 23-fold higher chances of harboring RET rearrangements (OR: 23.18; 95% CI, 5.32-100.98; P < 0.001).
Despite being intra-chromosomal inversions (Figure 2A ), both CCDC6-RET and NCOA4-RET fusions were detectable with immunohistochemistry ( Figure 2B ) or fluorescent in-situ hybridization ( Figure 2C and D) . Next-generation sequencing analyses ( Figure 2E ) revealed a high prevalence of potentially targetable RNF43/ZNRF3 mutations or DNA repair genes mutations in the MSI-high subset.
Prognostic role of RET rearrangements
At a median follow-up of 45.8 months, patients with RET-positive mCRC showed a significantly worse median OS when compared with RET-negative ones (14.0 versus 38.0 months, HR: 4.59; 95% CI, 3.64-32.66; P < 0.001) (Figure 3) . When applying the false discovery rate correction, the association of RET rearrangements with OS was still significant (P < 0.006). In the multivariable model (Table 2 ) including other covariates
RET rearranged mCRCs (N=24) RET negative mCRCs* N=291 associated with OS with P < 0.1 (age, ECOG PS, primary tumor location, primary resection, RAS and BRAF mutations and MSI), RET rearrangements were still associated with shorter OS (HR: 2.97; 95% CI, 1.25-7.07; P ¼ 0.014), while primary tumor location, RAS and BRAF mutations and MSI status were not (Table 2) . Patients bearing RET rearrangements had shorter OS than those with negative tumors in both right-(HR: 3.06; 95% CI, 1.77-27.81; P ¼ 0.006) and left-sided tumors (HR: 3.59; 95% CI, 2.39-63.9; P ¼ 0.003), and in both MSI-high (HR: 2.78; 95% CI, 1.10-11.79; P ¼ 0.040) and MSS ones (HR: 45.76; 95% CI, 4.45-123.60; P < 0.001) (Figure 4 ).
Predictive role of RET rearrangements
Only one patient with right sided, MSS RET-positive mCRC received an anti-EGFR-based therapy and rapidly progressed. Conversely, an immunotherapy-naïve patient affected by a right sided, MSI-high and CCDC6-RET positive mCRC achieved a complete response to RXDX-105 and is currently progressionfree after more than 19 months of therapy (supplementary Figure  S2 , available at Annals of Oncology online). When excluding from OS analysis patients treated with RXDX-105 during the course of their disease, the negative prognosis of RETpositive patients was similarly evident (10.0 versus 38.0 months, HR: 4.57; 95% CI, 3.48-32.64; P < 0.001; figure not shown).
Discussion
The cost-effectiveness of assessing rare actionable targets may be questionable in the daily clinical practice. Even if the incidence of RET fusions in mCRC patients is extremely low [6, 7, 8] , individuals harboring such actionable target may be suitable candidates for a personalized management strategy. Here we provide evidence that more than two out of three right-sided, RAS and BRAF wild-type and MSI-high mCRCs bear a RET fusion, thus leading to highly recommend RET immunohistochemical/FISH screening or even comprehensive genomic profiling in these cases. The association of specific gene fusions with MSI-high status has been shown by our previous work [3] and is confirmed here also for RET fusions. Resembling to BRAF V600E mutations [12] , RET fusions independently predict a poorer prognosis of mCRC patients, thus underlining the importance of early recognition of these alterations so as not to miss the opportunity to adopt a targeted strategy in these patients, instead of choosing conventional and mostly ineffective treatment options.
The potential negative predictive impact of RET fusions with respect to anti-EGFR agents has been proposed by preclinical and case-control studies [2, 13] . Even if the strength of this evidence is low, acknowledging the limited possibility of a further validation of RET fusion as a negative predictive biomarker due to its rarity, physicians should be to encouraged to enroll patients in trials with RET inhibitors, instead of using all available treatment APC  RNF43  ZNRF3  CTNNB1  CHD4  AXIN1  SOX9  FBXW7  TP53  ATM  ATR  RB1  RBM10  NBN  MLH1  MSH2  MSH6  POLE  POLD1  TGFBR2  SMAD3  SMAD4  IGF2  HRAS  BRAF  PIK3CA  PTEN  CASP8  ARID1A  ARID1B p11 lines including anti-EGFR agents. Basket design trials in multiple tumor types could be appropriate and potentially lead to tissueagnostic drug approvals. Considering RET as a therapeutic target might be a practice-changing strategy in this poor prognosis subtype, leading to a new precision oncology field that should not be limited to mCRC, but is indeed under development in nonsmall-cell lung cancer, thyroid cancer and neuroendocrine tumors, among others [14] [15] [16] . It should be pointed out that regorafenib showed signs of activity in a case of RET rearranged mCRC [6] . The selective, VEGFR-sparing RET inhibitors RXDX-105, BLU-667 and LOXO-292 may be the most promising agents. Even if the hypermutant status found in MSI-high tumors was proposed as a potential mechanism of de novo/rapid resistance to anti-EGFRs [13] , here we report a long-lasting complete response to selective RET inhibition in a MSI-high mCRC. On the contrary, the impact of gene fusions on response to immunotherapy of MSI-high cancers has not been explored, even if negative prognostic markers such as BRAF mutations did not seem to affect immunotherapy efficacy [17] . The combination of targeted therapy and immunotherapy might represent a successful strategy in the subset of patients with RET fusion-positive and MSI-high mCRC.
